QUARTERLY REPORT

Q2 2025 — Form 10-Q

Q2 2025PDF · 38 pages511 KB
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2025
OR
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from 	to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation 	I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class 	Trading Symbol(s) 	Name of Each Exchange on Which Registered
Common Shares, Without Par Value 	ABT 	New York Stock Exchange
NYSE Texas
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes  No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes  No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer  	Accelerated Filer 
Non-Accelerated Filer  	Smaller reporting company 
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No 
As of June 30, 2025, Abbott Laboratories had 1,740,459,014 common shares without par value outstanding.

-- 1 of 38 --

Table of Contents
Abbott Laboratories
Table of Contents
Part I - Financial Information
Page
Item 1. Financial Statements and Supplementary Data
Condensed Consolidated Statement of Earnings 	3
Condensed Consolidated Statement of Comprehensive Income 	4
Condensed Consolidated Balance Sheet 	5
Condensed Consolidated Statement of Shareholders’ Investment 	6
Condensed Consolidated Statement of Cash Flows 	8
Notes to the Condensed Consolidated Financial Statements 	9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 	25
Item 4. Controls and Procedures 	31
Part II - Other Information 	31
Item 1. Legal Proceedings 	31
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 	32
Item 6. Exhibits 	33
Signature 	34
2

-- 2 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended 	Six Months Ended
June 30 	June 30
2025 	2024 	2025 	2024
Net sales 	$ 	11,142 $ 	10,377 $ 	21,500 $ 	20,341
Cost of products sold, excluding amortization of intangible assets 	4,854 	4,603 	9,322 	9,066
Amortization of intangible assets 	420 	471 	840 	943
Research and development 	725 	698 	1,441 	1,382
Selling, general and administrative 	3,091 	2,936 	6,152 	5,895
Total operating cost and expenses 	9,090 	8,708 	17,755 	17,286
Operating earnings 	2,052 	1,669 	3,745 	3,055
Interest expense 	121 	140 	252 	281
Interest (income) 	(71) 	(82) 	(153) 	(162)
Net foreign exchange (gain) loss 	(11) 	(6) 	(18) 	(6)
Other (income) expense, net 	(137) 	10 	(264) 	(101)
Earnings before taxes 	2,150 	1,607 	3,928 	3,043
Taxes on earnings 	371 	305 	824 	516
Net Earnings 	$ 	1,779 $ 	1,302 $ 	3,104 $ 	2,527
Basic Earnings Per Common Share 	$ 	1.02 $ 	0.74 $ 	1.78 $ 	1.45
Diluted Earnings Per Common Share 	$ 	1.01 $ 	0.74 $ 	1.77 $ 	1.44
Average Number of Common Shares Outstanding Used for Basic Earnings Per
Common Share 	1,743,437 	1,743,040 	1,741,348 	1,741,595
Dilutive Common Stock Options 	7,398 	8,113 	7,706 	8,781
Average Number of Common Shares Outstanding Plus Dilutive Common Stock
Options 	1,750,835 	1,751,153 	1,749,054 	1,750,376
Outstanding Common Stock Options Having No Dilutive Effect 	1,442 	8,855 	1,431 	6,892
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3

-- 3 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)
Three Months Ended 	Six Months Ended
June 30 	June 30
2025 	2024 	2025 	2024
Net Earnings 	$ 	1,779 $ 	1,302 $ 	3,104 $ 	2,527
Foreign currency translation gain (loss) adjustments, net of taxes of $26 and $58
in 2025 and $— and $— in 2024 	1,000 	(36) 	1,550 	(422)
Net actuarial gains (losses) and amortization of net actuarial losses and prior
service costs and credits, net of taxes of $—and $— in 2025 and $— and $1 in
2024 	26 	7 	56 	11
Net gains (losses) for derivative instruments designated as cash flow hedges, net
of taxes of $(69) and $(109) in 2025 and $27 and $57 in 2024 	(185) 	60 	(276) 	115
Other comprehensive income (loss) 	841 	31 	1,330 	(296)
Comprehensive Income 	$ 	2,620 $ 	1,333 $ 	4,434 $ 	2,231
June 30,
2025 December 31,
2024
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments 	$ 	(5,955) $ 	(7,505)
Net actuarial (losses) and prior service (costs) and credits 	(555) 	(611)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges 	(66) 	210
Accumulated other comprehensive income (loss) 	$ 	(6,576) $ 	(7,906)
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4

-- 4 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
June 30,
2025
December 31,
2024
Assets
Current Assets:
Cash and cash equivalents 	$ 	6,951 $ 	7,616
Short-term investments 	331 	351
Trade receivables, less allowances of $471 in 2025 and $439 in 2024 	7,972 	6,925
Inventories:
Finished products 	4,319 	3,700
Work in process 	962 	840
Materials 	1,673 	1,654
Total inventories 	6,954 	6,194
Prepaid expenses and other receivables 	2,260 	2,570
Total Current Assets 	24,468 	23,656
Investments 	958 	886
Property and equipment, at cost 	24,472 	22,740
Less: accumulated depreciation and amortization 	13,077 	12,082
Net property and equipment 	11,395 	10,658
Intangible assets, net of amortization 	5,920 	6,647
Goodwill 	23,952 	23,108
Deferred income taxes and other assets 	17,306 	16,459
$ 	83,999 $ 	81,414
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable 	$ 	4,306 $ 	4,195
Salaries, wages and commissions 	1,550 	1,701
Other accrued liabilities 	5,656 	5,143
Dividends payable 	1,030 	1,024
Income taxes payable 	390 	594
Current portion of long-term debt 	507 	1,500
Total Current Liabilities 	13,439 	14,157
Long-term debt 	12,930 	12,625
Post-employment obligations, deferred income taxes and other long-term liabilities 	6,801 	6,731
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2025: 1,996,448,469; 2024: 1,991,472,630 	25,284 	25,153
Common shares held in treasury, at cost — Shares: 2025: 255,988,730; 2024: 259,774,639 	(16,610) 	(16,844)
Earnings employed in the business 	48,467 	47,261
Accumulated other comprehensive income (loss) 	(6,576) 	(7,906)
Total Abbott Shareholders’ Investment 	50,565 	47,664
Noncontrolling Interests in Subsidiaries 	264 	237
Total Shareholders’ Investment 	50,829 	47,901
$ 	83,999 $ 	81,414
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5

-- 5 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Three Months Ended June 30
2025 	2024
Common Shares:
Balance at March 31
Shares: 2025: 1,995,858,606; 2024: 1,989,789,999 	$ 	25,125 $ 	24,726
Issued under incentive stock programs
Shares: 2025: 589,863; 2024: 239,293 	36 	13
Share-based compensation 	128 	124
Issuance of restricted stock awards 	(5) 	(5)
Balance at June 30
Shares: 2025: 1,996,448,469; 2024: 1,990,029,292 	$ 	25,284 $ 	24,858
Common Shares Held in Treasury:
Balance at March 31
Shares: 2025: 256,021,416; 2024: 250,155,515 	$ 	(16,612) $ 	(15,761)
Issued under incentive stock programs
Shares: 2025: 34,961; 2024: 27,310 	3 	2
Purchased
Shares: 2025: 2,275; 2024: 3,358 	(1) 	—
Balance at June 30
Shares: 2025: 255,988,730; 2024: 250,131,563 	$ 	(16,610) $ 	(15,759)
Earnings Employed in the Business:
Balance at March 31 	$ 	47,715 $ 	38,011
Net earnings 	1,779 	1,302
Cash dividends declared on common shares (per share — 2025: $0.59; 2024: $0.55) 	(1,028) 	(961)
Effect of common and treasury share transactions 	1 	2
Balance at June 30 	$ 	48,467 $ 	38,354
Accumulated Other Comprehensive Income (Loss):
Balance at March 31 	$ 	(7,417) $ 	(8,166)
Other comprehensive income (loss) 	841 	31
Balance at June 30 	$ 	(6,576) $ 	(8,135)
Noncontrolling Interests in Subsidiaries:
Balance at March 31 	$ 	253 $ 	233
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases 	11 	9
Balance at June 30 	$ 	264 $ 	242
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
6

-- 6 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Six Months Ended June 30
2025 	2024
Common Shares:
Balance at January 1
Shares: 2025:1,991,472,630; 2024: 1,987,883,852 	$ 	25,153 $ 	24,869
Issued under incentive stock programs
Shares: 2025: 4,975,839; 2024: 2,145,440 	275 	100
Share-based compensation 	431 	446
Issuance of restricted stock awards 	(575) 	(557)
Balance at June 30
Shares: 2025: 1,996,448,469; 2024: 1,990,029,292 	$ 	25,284 $ 	24,858
Common Shares Held in Treasury:
Balance at January 1
Shares: 2025: 259,774,639; 2024: 253,807,494 	$ 	(16,844) $ 	(15,981)
Issued under incentive stock programs
Shares: 2025: 3,970,900; 2024: 3,865,565 	259 	244
Purchased
Shares: 2025: 184,991; 2024: 189,634 	(25) 	(22)
Balance at June 30
Shares: 2025: 255,988,730; 2024: 250,131,563 	$ 	(16,610) $ 	(15,759)
Earnings Employed in the Business:
Balance at January 1 	$ 	47,261 $ 	37,554
Net earnings 	3,104 	2,527
Cash dividends declared on common shares (per share — 2025: $1.18; 2024: $1.10) 	(2,061) 	(1,921)
Effect of common and treasury share transactions 	163 	194
Balance at June 30 	$ 	48,467 $ 	38,354
Accumulated Other Comprehensive Income (Loss):
Balance at January 1 	$ 	(7,906) $ 	(7,839)
Other comprehensive income (loss) 	1,330 	(296)
Balance at June 30 	$ 	(6,576) $ 	(8,135)
Noncontrolling Interests in Subsidiaries:
Balance at January 1 	$ 	237 $ 	224
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases 	27 	18
Balance at June 30 	$ 	264 $ 	242
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
7

-- 7 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
Six Months Ended June 30
2025 	2024
Cash Flow From (Used in) Operating Activities:
Net earnings 	$ 	3,104 $ 	2,527
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation 	693 	667
Amortization of intangible assets 	840 	943
Share-based compensation 	431 	445
Trade receivables 	(672) 	(476)
Inventories 	(252) 	(513)
Other, net 	(680) 	(608)
Net Cash From Operating Activities 	3,464 	2,985
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(986) 	(931)
Acquisitions of businesses and technologies, net of cash acquired 	(30) 	—
Proceeds from business dispositions 	— 	1
Sales (purchases) of other investment securities, net 	(44) 	49
Other 	8 	3
Net Cash From (Used in) Investing Activities 	(1,052) 	(878)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other 	(52) 	(170)
Proceeds from issuance of long-term debt 	3 	221
Repayments of long-term debt 	(1,002) 	(18)
Purchases of common shares 	(286) 	(229)
Proceeds from stock options exercised 	322 	147
Dividends paid 	(2,055) 	(1,918)
Other 	(82) 	—
Net Cash From (Used in) Financing Activities 	(3,152) 	(1,967)
Effect of exchange rate changes on cash and cash equivalents 	75 	(49)
Net Increase (Decrease) in Cash and Cash Equivalents 	(665) 	91
Cash and Cash Equivalents, Beginning of Year 	7,616 	6,896
Cash and Cash Equivalents, End of Period 	$ 	6,951 $ 	6,987
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
8

-- 8 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 1 — Basis of Presentation
The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and
Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However,
in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial
position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s
Annual Report on Form 10-K for the year ended December 31, 2024. The condensed consolidated financial statements include the accounts of the parent
company and subsidiaries, after elimination of intercompany transactions.
Note 2 — New Accounting Standards
Recently Adopted Accounting Standards
In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures, which expands the breadth and frequency of required segment disclosures. The guidance is
required to be applied retrospectively to all periods presented in the financial statements. Abbott adopted the standard on January 1, 2024. The new
standard did not have an impact on Abbott's consolidated financial statements, but required additional disclosures, retrospectively applied to all periods
presented in Note 14 — Segment Information.
Recent Accounting Standards Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income - Expense Disaggregation
Disclosures, which requires an entity to disclose on an annual and interim basis, disaggregated information about specific income statement expense
categories. The guidance should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott
for full year 2027 reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires an entity to
disclose annually additional information related to the company's income tax rate reconciliation and income taxes paid during the period. The guidance
should be applied prospectively with the option to apply the standard retrospectively. The standard becomes effective for Abbott for full year 2025
reporting. Abbott is currently evaluating the impact of this new standard on its consolidated financial statements.
9

-- 9 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 3 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Abbott has four
reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The following tables provide detail by sales category:
Three Months Ended June 30, 2025 	Three Months Ended June 30, 2024
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	— $ 	1,059 $ 	1,059 $ 	— $ 	988 $ 	988
Other 	— 	324 	324 	— 	306 	306
Total 	— 	1,383 	1,383 	— 	1,294 	1,294
Nutritional Products —
Pediatric Nutritionals 	587 	467 	1,054 	564 	495 	1,059
Adult Nutritionals 	370 	788 	1,158 	369 	722 	1,091
Total 	957 	1,255 	2,212 	933 	1,217 	2,150
Diagnostic Products —
Core Laboratory 	351 	1,007 	1,358 	327 	1,002 	1,329
Molecular 	35 	88 	123 	33 	94 	127
Point of Care 	104 	44 	148 	107 	49 	156
Rapid Diagnostics 	321 	223 	544 	345 	238 	583
Total 	811 	1,362 	2,173 	812 	1,383 	2,195
Medical Devices —
Rhythm Management 	340 	333 	673 	292 	315 	607
Electrophysiology 	322 	378 	700 	287 	340 	627
Heart Failure 	282 	86 	368 	244 	77 	321
Vascular 	283 	474 	757 	275 	449 	724
Structural Heart 	289 	347 	636 	258 	306 	564
Neuromodulation 	193 	61 	254 	192 	51 	243
Diabetes Care 	794 	1,187 	1,981 	637 	1,011 	1,648
Total 	2,503 	2,866 	5,369 	2,185 	2,549 	4,734
Other 	5 	— 	5 	4 	— 	4
Total 	$ 	4,276 $ 	6,866 $ 	11,142 $ 	3,934 $ 	6,443 $ 	10,377
10

-- 10 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 3 — Revenue (Continued)
Six Months Ended June 30, 2025 	Six Months Ended June 30, 2024
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	— $ 	2,024 $ 	2,024 $ 	— $ 	1,916 $ 	1,916
Other 	— 	619 	619 	— 	604 	604
Total 	— 	2,643 	2,643 	— 	2,520 	2,520
Nutritional Products —
Pediatric Nutritionals 	1,175 	920 	2,095 	1,078 	990 	2,068
Adult Nutritionals 	737 	1,526 	2,263 	733 	1,417 	2,150
Total 	1,912 	2,446 	4,358 	1,811 	2,407 	4,218
Diagnostic Products —
Core Laboratory 	683 	1,852 	2,535 	637 	1,897 	2,534
Molecular 	75 	170 	245 	75 	181 	256
Point of Care 	204 	86 	290 	205 	90 	295
Rapid Diagnostics 	720 	437 	1,157 	826 	498 	1,324
Total 	1,682 	2,545 	4,227 	1,743 	2,666 	4,409
Medical Devices —
Rhythm Management 	644 	614 	1,258 	563 	606 	1,169
Electrophysiology 	621 	708 	1,329 	556 	658 	1,214
Heart Failure 	544 	163 	707 	481 	145 	626
Vascular 	551 	916 	1,467 	529 	884 	1,413
Structural Heart 	571 	642 	1,213 	491 	588 	1,079
Neuromodulation 	369 	113 	482 	373 	96 	469
Diabetes Care 	1,542 	2,266 	3,808 	1,226 	1,991 	3,217
Total 	4,842 	5,422 	10,264 	4,219 	4,968 	9,187
Other 	8 	— 	8 	7 	— 	7
Total 	$ 	8,444 $ 	13,056 $ 	21,500 $ 	7,780 $ 	12,561 $ 	20,341
Products sold by the Diagnostics segment include various types of diagnostic tests to detect the COVID-19 coronavirus. In the second quarter of 2025 and
2024, COVID-19 testing-related sales totaled $55 million and $102 million, respectively. In the first six months of 2025 and 2024, Abbott’s COVID-19
testing-related sales totaled $139 million and $306 million, respectively.
11

-- 11 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 3 — Revenue (Continued)
Remaining Performance Obligations
As of June 30, 2025, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially
unsatisfied) was $5.9 billion in the Diagnostic Products segment and $427 million in the Medical Devices segment. Abbott expects to recognize revenue on
approximately 53 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months
and the remainder thereafter.
These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended
warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has
applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance
obligations related to contracts with original expected durations of one year or less in the amounts above.
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets
primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and
the end of the period, as well as the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise
primarily in the Medical Devices segment when payment is received upfront for various multi-period extended service arrangements.
Changes in the contract liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2024 	$ 	568
Unearned revenue from cash received during the period 	252
Revenue recognized related to contract liability balance 	(192)
Balance at June 30, 2025 	$ 	628
Note 4 — Supplemental Financial Information
Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation
of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating
securities. Net earnings allocated to common shares for the three months ended June 30, 2025, and 2024 were $1.8 billion and $1.3 billion, respectively,
and for the six months ended June 30, 2025, and 2024 were $3.1 billion and $2.5 billion, respectively.
In the second quarter of 2024, Abbott sold a non-core business related to its Established Pharmaceutical Products segment. Abbott recorded a loss of
$143 million on the sale in Other (income) expense, net in its Condensed Consolidated Statement of Earnings. Net assets, which primarily related to
inventory and net property and equipment and had a carrying value of $28 million, were included in the sale. The loss on the sale also included
$116 million of cumulative foreign currency translation adjustment previously recorded in Accumulated other comprehensive income (loss), net of tax.
12

-- 12 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 4 — Supplemental Financial Information (Continued)
Other, net in Net Cash From Operating Activities in the Condensed Consolidated Statement of Cash Flows for the first six months of 2025 includes $246
million of pension contributions and the payment of cash taxes of $945 million. The first six months of 2024 included $289 million of pension
contributions and the payment of cash taxes of $747 million.
The following summarizes the activity for the first six months of 2025 related to the allowance for doubtful accounts as of June 30, 2025:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2024 	$ 	247
Provisions/charges to income 	52
Amounts charged off and other deductions 	(19)
Balance at June 30, 2025 	$ 	280
The Allowance for Doubtful Accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott
considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging
trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-
looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The components of long-term investments are as follows:
(in millions) June 30,
2025 December 31,
2024
Long-term Investments:
Equity securities 	$ 	619 $ 	553
Other 	339 	333
Total 	$ 	958 $ 	886
The increase in Abbott’s Long-term Investments as of June 30, 2025, versus the balance as of December 31, 2024, primarily relates to additional
investments and earnings from equity method investments, partially offset by the impairment of certain securities.
Abbott’s equity securities as of June 30, 2025, include $315 million of investments in mutual funds that are held in a rabbi trust. These investments, which
are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate
purposes and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of June 30, 2025, with a carrying value of $158 million that are accounted for under the equity method of
accounting and other equity investments with a carrying value of $117 million that do not have a readily determinable fair value.
13

-- 13 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)
The changes in Accumulated other comprehensive income (loss), net of tax, are as follows:
Three Months Ended June 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024
Balance at March 31 	$ 	(6,955) $ 	(6,890) $ 	(581) $ 	(1,372) $ 	119 $ 	96
Other comprehensive income (loss) before
reclassifications 	1,000 	(152) 	26 	3 	(150) 	77
Amounts reclassified from accumulated
other comprehensive income 	— 	116 	— 	4 	(35) 	(17)
Net current period comprehensive income
(loss) 	1,000 	(36) 	26 	7 	(185) 	60
Balance at June 30 	$ 	(5,955) $ 	(6,926) $ 	(555) $ 	(1,365) $ 	(66) $ 	156
Six Months Ended June 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024
Balance at January 1 	$ 	(7,505) $ 	(6,504) $ 	(611) $ 	(1,376) $ 	210 $ 	41
Other comprehensive income (loss) before
reclassifications 	1,550 	(538) 	56 	5 	(214) 	145
Amounts reclassified from accumulated
other comprehensive income 	— 	116 	— 	6 	(62) 	(30)
Net current period comprehensive income
(loss) 	1,550 	(422) 	56 	11 	(276) 	115
Balance at June 30 	$ 	(5,955) $ 	(6,926) $ 	(555) $ 	(1,365) $ 	(66) $ 	156
The reclassification of $116 million out of Accumulated other comprehensive income (loss) in 2024 is included in the loss related to the sale of a non-core
business included in Other (income) expense, net. Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and
prior service cost are included as a component of net periodic benefit costs; see Note 12 — Post-Employment Benefits for additional details.
Note 6 — Goodwill and Intangible Assets
The total amount of goodwill reported was $24.0 billion at June 30, 2025, and $23.1 billion at December 31, 2024. The amount of goodwill related to
reportable segments at June 30, 2025, was $2.7 billion for the Established Pharmaceutical Products segment, $285 million for the Nutritional Products
segment, $3.6 billion for the Diagnostic Products segment, and $17.3 billion for the Medical Devices segment. Foreign currency translation adjustments
increased goodwill by $836 million in the first six months of 2025. There were no reductions of goodwill relating to impairments in the first six months of
2025.
14

-- 14 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 6 — Goodwill and Intangible Assets (Continued)
The gross amount of amortizable intangible assets, primarily product rights and technology, was $27.6 billion as of June 30, 2025, and $27.1 billion as of
December 31, 2024. Accumulated amortization was $22.4 billion and $21.3 billion as of June 30, 2025, and December 31, 2024, respectively. In the first
six months of 2025, intangible assets, net of amortization, increased $87 million due to foreign currency translation. Abbott’s estimated annual amortization
expense for intangible assets is approximately $1.7 billion in 2025, $1.5 billion in 2026, $1.2 billion in 2027, $0.7 billion in 2028 and $0.6 billion in 2029.
Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were $789 million and
$784 million as of June 30, 2025, and December 31, 2024, respectively.
Note 7 — Restructuring Plans
In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical
devices businesses. In the six months ended June 30, 2025, Abbott recorded employee related severance and other charges of $104 million, of which $69
million was recorded in Cost of products sold, $20 million was recorded in Research and development, and $15 million was recorded in Selling, general,
and administrative. Payments related to these actions totaled $21 million in the first six months of 2025 and the remaining liabilities totaled $83 million at
June 30, 2025. In addition, Abbott recognized asset impairment charges of $12 million related to these restructuring plans.
In 2024 and 2023, Abbott management approved plans to restructure or streamline various operations in order to reduce costs in its medical devices,
diagnostic, nutritional, and established pharmaceutical businesses, including the discontinuation of its ZonePerfect product line in 2024. In addition,
Abbott recognized asset impairment charges of $28 million related to these restructuring plans in the first six months of 2024. The following summarizes
the activity related to these restructuring actions and the status of the related accruals as of June 30, 2025:
(in millions) 	Total
Accrued balance at December 31, 2024 	$ 	118
Payments and other adjustments 	(56)
Accrued balance at June 30, 2025 	$ 	62
Note 8 — Incentive Stock Programs
In the first six months of 2025, Abbott granted 1,468,147 stock options, 362,263 restricted stock awards and 4,337,917 restricted stock units under its
incentive stock program. At June 30, 2025, 50 million shares were reserved for future grants. Information regarding the number of options outstanding and
exercisable at June 30, 2025 is as follows:
Outstanding 	Exercisable
Number of shares 	23,005,657 	19,780,883
Weighted average remaining life (years) 	4.9 	4.3
Weighted average exercise price 	$ 	89.67 $ 	84.27
Aggregate intrinsic value (in millions) 	$ 	1,066 $ 	1,024
The total unrecognized share-based compensation cost at June 30, 2025, amounted to $683 million, which is expected to be recognized over the next three
years.
®
15

-- 15 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 9 — Debt and Lines of Credit
On March 17, 2025, Abbott repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity.
Note 10 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates,
primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross
notional amounts totaling $7.2 billion at June 30, 2025, and $7.0 billion at December 31, 2024, are designated as cash flow hedges of the variability of the
cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of June 30, 2025, will be included in
Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables
and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the
functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in
exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are
primarily the U.S. dollar and European currencies. At June 30, 2025, and December 31, 2024, Abbott held the gross notional amounts of $12.8 billion and
$16.2 billion, respectively, of such foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of $635 million and $583 million as of June 30, 2025, and December 31, 2024, respectively, as
a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is
recorded in Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts with a notional amount totaling $1.2 billion at June 30, 2025, and $2.2 billion at December 31, 2024, to
manage its exposure to changes in the fair value of fixed-rate debt. The decrease from December 31, 2024, was due to the maturity of $1.0 billion of
interest rate hedge contracts in conjunction with long-term debt, both of which matured in March 2025. These contracts are designated as fair value hedges
of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-
rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-
rate debt by an offsetting amount.
16

-- 16 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative and non-derivative financial instruments as of June 30, 2025, and
December 31, 2024:
Fair Value - Assets 	Fair Value - Liabilities
(in millions) 	June 30, 2025 	December 31, 2024 Balance Sheet Caption 	June 30, 2025 	December 31, 2024 Balance Sheet Caption
Interest rate swaps designated as fair value
hedges:
Non-current 	$ 	— $ 	— Deferred income
taxes and other assets
$ 	33 $ 	51 Post-employment
obligations, deferred
income taxes and
other long-term
liabilities
Current 	— 	1 Prepaid expenses and
other receivables
— 	— Other accrued
liabilities
Foreign currency forward exchange
contracts:
Hedging instruments 	22 	243 Prepaid expenses and
other receivables
297 	19 Other accrued
liabilities
Others not designated as hedges 	89 	147 Prepaid expenses and
other receivables
99 	112 Other accrued
liabilities
Debt designated as a hedge of net
investment in a foreign subsidiary
— 	— n/a 	635 	583 Long-term debt
$ 	111 $ 	391 	$ 	1,064 $ 	765
17

-- 17 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative
financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income.
Gain (loss) Recognized in Other
Comprehensive Income (loss)
Income (expense) and Gain (loss)
Reclassified into Income
Three Months Ended June
30, 	Six Months Ended June 30, Three Months Ended June
30, 	Six Months Ended June 30,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Income
Statement
Caption
Foreign currency forward
exchange contracts
designated as cash flow
hedges
$ 	(209) $ 	111 $ 	(303) $ 	238 $ 	48 $ 	25 $ 	87 $ 	43 Cost of
products sold
Debt designated as a hedge of
net investment in a foreign
subsidiary
(23) 	23 	(52) 	47 	— 	— 	— 	— n/a
Interest rate swaps designated
as fair value hedges n/a 	n/a 	n/a 	n/a 	14 	28 	17 	4 Interest
expense
Gains of $1 million and $43 million were recognized in the three months ended June 30, 2025, and 2024, respectively, related to foreign currency forward
exchange contracts not designated as a hedge. Gains of $35 million and $135 million were recognized in the six months ended June 30, 2025, and 2024,
respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated
Statement of Earnings on the Net foreign exchange (gain) loss line.
The carrying values and fair values of certain financial instruments as of June 30, 2025, and December 31, 2024, are shown in the following table. The
carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major
international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.
June 30, 2025 	December 31, 2024
(in millions) Carrying
Value Fair
Value Carrying
Value Fair
Value
Long-term Investment Securities:
Equity securities 	$ 	619 $ 	619 $ 	553 $ 	553
Other 	339 	339 	333 	333
Total Long-term Debt 	(13,437) 	(13,221) 	(14,125) 	(13,710)
Foreign Currency Forward Exchange Contracts:
Receivable position 	111 	111 	390 	390
(Payable) position 	(396) 	(396) 	(131) 	(131)
Interest Rate Hedge Contracts:
Receivable position 	— 	— 	1 	1
(Payable) position 	(33) 	(33) 	(51) 	(51)
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
18

-- 18 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
Basis of Fair Value Measurement
(in millions) Outstanding
Balances
Quoted
Prices in
Active
Markets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
June 30, 2025:
Equity securities 	$ 	344 $ 	344 $ 	— $ 	—
Foreign currency forward exchange contracts 	111 	— 	111 	—
Total Assets 	$ 	455 $ 	344 $ 	111 $ 	—
Fair value of hedged long-term debt 	$ 	1,119 $ 	— $ 	1,119 $ 	—
Interest rate swap derivative financial instruments 	33 	— 	33 	—
Foreign currency forward exchange contracts 	396 	— 	396 	—
Contingent consideration related to business combinations 	1 	— 	— 	1
Total Liabilities 	$ 	1,549 $ 	— $ 	1,548 $ 	1
December 31, 2024:
Equity securities 	$ 	323 $ 	323 $ 	— $ 	—
Interest rate swap derivative financial instruments 	1 	— 	1 	—
Foreign currency forward exchange contracts 	390 	— 	390 	—
Total Assets 	$ 	714 $ 	323 $ 	391 $ 	—
Fair value of hedged long-term debt 	$ 	2,096 $ 	— $ 	2,096 $ 	—
Interest rate swap derivative financial instruments 	51 	— 	51 	—
Foreign currency forward exchange contracts 	131 	— 	131 	—
Contingent consideration related to business combinations 	38 	— 	— 	38
Total Liabilities 	$ 	2,316 $ 	— $ 	2,278 $ 	38
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative
instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based
on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on
independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. The decrease in the amount of
contingent consideration from December 31, 2024, reflects a contingent consideration payment related to a previous business combination.
19

-- 19 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 11 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto
Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded
an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is
expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.
Abbott has been named as a defendant in a number of lawsuits alleging that its preterm infant formula and human milk fortifier products that contain cow’s
milk ingredients cause an intestinal disease known as necrotizing enterocolitis (NEC) and inadequately warn about the risk of NEC. These lawsuits claim
that certain preterm infants suffered injury or death as a result of contracting NEC. Two cases have gone to trial. In a Missouri state case, a jury awarded a
plaintiff $495 million in damages. In a second Missouri state court case, a jury found in Abbott’s favor, and the judge later ordered a new trial in that
matter. The two Missouri cases are on appeal. In the first federal Multidistrict Litigation (MDL) “bellwether” case, the U.S. District Court for the Northern
District of Illinois granted summary judgment in favor of Abbott on all claims. The plaintiff in that case has filed a motion for reconsideration. Abbott
stands by its products and the information it provided about them. Abbott does not believe that it is probable that a material loss will be incurred related to
these lawsuits and therefore, no reserves have been recorded. Given the uncertainty as to the possible outcome in each of these lawsuits, Abbott is unable to
reasonably estimate a range of possible loss related to these lawsuits.
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental
exposures to be from approximately $5 million to $15 million. The recorded accrual balance at June 30, 2025, for these proceedings and exposures was
approximately $10 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.”
Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the
outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect
on Abbott’s financial position, cash flows, or results of operations, except for the cases discussed in the second paragraph of this note, the resolution of
which could be material to Abbott's financial position, cash flows or results of operations.
Note 12 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are
recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net costs recognized for Abbott’s major defined
benefit plans and post-employment medical and dental benefit plans are as follows:
Defined Benefit Plans 	Medical and Dental Plans
Three Months Ended June 30, 	Six Months Ended June 30, 	Three Months Ended June 30, 	Six Months Ended June 30,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Service cost - benefits earned during
the period 	$ 	53 $ 	60 $ 	107 $ 	121 $ 	11 $ 	10 $ 	21 $ 	20
Interest cost on projected benefit
obligations 	123 	116 	245 	234 	18 	12 	34 	27
Expected return on plan assets 	(281) 	(263) 	(559) 	(525) 	(6) 	(6) 	(13) 	(12)
Net amortization of:
Actuarial loss, net 	2 	6 	4 	12 	— 	(1) 	— 	(1)
Prior service cost (credit) 	1 	1 	1 	1 	(3) 	(4) 	(5) 	(7)
Net cost (credit) 	$ 	(102) $ 	(80) $ 	(202) $ 	(157) $ 	20 $ 	11 $ 	37 $ 	27
20

-- 20 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 12 — Post-Employment Benefits (Continued)
Abbott funds its domestic defined benefit plans according to U.S. Internal Revenue Service (IRS) funding limitations. International pension plans are
funded according to similar regulations. In the first six months of 2025 and 2024, $246 million and $289 million, respectively, were contributed to defined
benefit plans. In the first six months of 2025 and 2024, $75 million and $28 million were contributed, respectively, to the post-employment medical and
dental plans.
Note 13 — Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2025 and 2024, taxes
on earnings include $84 million and $29 million, respectively, in excess tax benefits associated with share-based compensation. In the first six months of
2025, taxes on earnings includes approximately $300 million of tax expense related to a deferred tax asset that was recognized as a significant non-cash tax
benefit in a prior year. In the first six months of 2025 and 2024, taxes on earnings also included approximately $90 million of net tax benefit and $35
million of net tax expense, respectively, as the result of the resolution of various tax positions related to prior years.
In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the amount of $417 million.
The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its foreign affiliates. Abbott
believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments contradict methods that
were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are erroneous and
unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the
2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott filed a petition in September 2024
with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary
adjustments proposed in the SNOD are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott
believes that the income reallocation adjustments proposed in the SNOD are without merit. The SNOD also contains other proposed adjustments and
omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 SNOD also contested a
deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law.
Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2024.
Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through
litigation as necessary. Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues
to believe that its reserves for uncertain tax positions are appropriate.
The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1
proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Pillar 2 proposes to assess a 15 percent
minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt
the Pillar 2 model rules. The enactment of current Pillar 2 model rules did not and is not projected to have a material impact to Abbott's consolidated
financial statements. Abbott continues to monitor the Pillar 1 and Pillar 2 developments.
21

-- 21 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 14 — Segment Information
Abbott’s principal business is the discovery, development, manufacture, and sale of a broad line of healthcare products. Abbott’s products are generally
sold directly to retailers, wholesalers, hospitals, healthcare facilities, laboratories, physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites.
For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses are
aggregated and reported as the Diagnostic Products segment.
Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care
products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart,
Neuromodulation and Diabetes Care businesses are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are
on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive
Officer (CEO). The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment
operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee
benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible
asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
22

-- 22 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 14 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not
presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
Net Sales to External Customers 	Cost of Products Sold 	Research and Development
Selling, General and
Administrative 	Operating Earnings
Three Months Ended June 30, 	Three Months Ended June 30, 	Three Months Ended June 30, 	Three Months Ended June 30, 	Three Months Ended June 30,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	1,383 $ 	1,294 $ 	(631) $ 	(591) $ 	(43) $ 	(44) $ 	(363) $ 	(344) $ 	346 $ 	315
Nutritionals 	2,212 	2,150 	(1,155) 	(1,148) 	(54) 	(53) 	(585) 	(576) 	418 	373
Diagnostics 	2,173 	2,195 	(1,224) 	(1,203) 	(154) 	(162) 	(423) 	(400) 	372 	430
Medical Devices 	5,369 	4,734 	(1,758) 	(1,627) 	(430) 	(379) 	(1,385) 	(1,221) 	1,796 	1,507
Total 	$ 	11,137 $ 	10,373 $ 	(4,768) $ 	(4,569) $ 	(681) $ 	(638) $ 	(2,756) $ 	(2,541) $ 	2,932 $ 	2,625
Other 	5 	4
Net sales 	$ 	11,142 $ 	10,377
Corporate functions and plan benefit costs 	(65) 	(80)
Net interest expense 	(50) 	(58)
Share-based compensation (a) 	(142) 	(141)
Amortization of Intangible assets 	(420) 	(471)
Other, net (b) 	(105) 	(268)
Earnings before Taxes 	$ 	2,150 $ 	1,607
Net Sales to External Customers 	Cost of Products Sold 	Research and Development
Selling, General and
Administrative 	Operating Earnings
Six Months Ended
June 30,
Six Months Ended
June 30,
Six Months Ended
June 30,
Six Months Ended
June 30,
Six Months Ended
June 30,
(in millions) 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	2,643 $ 	2,520 $ 	(1,200) $ 	(1,175) $ 	(85) $ 	(85) $ 	(714) $ 	(678) $ 	644 $ 	582
Nutritionals 	4,358 	4,218 	(2,279) 	(2,236) 	(106) 	(105) 	(1,161) 	(1,127) 	812 	750
Diagnostics 	4,227 	4,409 	(2,376) 	(2,391) 	(305) 	(317) 	(815) 	(797) 	731 	904
Medical Devices 	10,264 	9,187 	(3,356) 	(3,174) 	(831) 	(747) 	(2,672) 	(2,399) 	3,405 	2,867
Total 	$ 	21,492 $ 	20,334 $ 	(9,211) $ 	(8,976) $ 	(1,327) $ 	(1,254) $ 	(5,362) $ 	(5,001) $ 	5,592 $ 	5,103
Other 	8 	7
Net sales 	$ 	21,500 $ 	20,341
Corporate functions and plan benefit costs 	(93) 	(146)
Net interest expense 	(99) 	(119)
Share-based compensation (a) 	(431) 	(445)
Amortization of Intangible assets 	(840) 	(943)
Other, net (b) 	(201) 	(407)
Earnings before Taxes 	$ 	3,928 $ 	3,043
______________________________________
(a) 	Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b) 	Other, net for the three and six months ended June 30, 2025 and 2024 includes charges related to restructurings, fair value adjustments to contingent consideration and integration
costs related to business combinations. Other, net for the six months ended June 30, 2025 and 2024 also includes impairment charges related to various investments. Other, net for
the three and six months ended June 30, 2024 also includes charges related to the impairment of IPR&D assets, as well as a loss on the divestiture of a non-core business.
23

-- 23 of 38 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
June 30, 2025
(Unaudited)
Note 14 — Segment Information (Continued)
Depreciation
Additions to
Property and Equipment
Three Months Ended June 30, 	Three Months Ended June 30,
(in millions) 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	25 $ 	24 $ 	39 $ 	37
Nutritionals 	44 	39 	81 	103
Diagnostics 	135 	129 	166 	169
Medical Devices 	94 	87 	145 	158
Total Reportable Segments 	298 	279 	431 	467
Other 	59 	55 	62 	68
Total 	$ 	357 $ 	334 $ 	493 $ 	535
Depreciation
Additions to
Property and Equipment
Six Months Ended June 30, 	Six Months Ended June 30,
(in millions) 	2025 	2024 	2025 	2024
Established Pharmaceuticals 	$ 	48 $ 	48 $ 	72 $ 	66
Nutritionals 	86 	78 	160 	176
Diagnostics 	261 	258 	301 	292
Medical Devices 	182 	174 	301 	293
Total Reportable Segments 	577 	558 	834 	827
Other 	116 	109 	122 	117
Total 	$ 	693 $ 	667 $ 	956 $ 	944
Total Assets
As of June 30, 	As of December 31,
(in millions) 	2025 	2024
Established Pharmaceuticals 	$ 	3,732 $ 	3,087
Nutritionals 	4,910 	4,404
Diagnostics 	8,177 	7,678
Medical Devices 	10,555 	9,472
Total Reportable Segment Assets 	$ 	27,374 $ 	24,641
Cash and investments 	8,240 	8,853
Goodwill and intangible assets 	29,872 	29,755
All other (c) 	18,513 	18,165
Total Assets 	$ 	83,999 $ 	81,414
(c) 	As of June 30, 2025 and December 31, 2024, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.
24

-- 24 of 38 --

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Review — Results of Operations
Abbott’s revenues are derived primarily from the sale of a broad line of healthcare products under short-term receivable arrangements. Patent protection
and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price
controls, competition, and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and
costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products, and branded generic pharmaceuticals.
The following tables detail sales by reportable segment for the three and six months ended June 30. Percent changes are versus the prior year and are based
on unrounded numbers.
Net Sales to External Customers
(in millions)
Three Months
Ended
June 30, 2025
Three Months
Ended
June 30, 2024
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products 	$ 	1,383 $ 	1,294 	6.9 % 	(0.8)% 	7.7 %
Nutritional Products 	2,212 	2,150 	2.9 	(0.5) 	3.4
Diagnostic Products 	2,173 	2,195 	(1.0) 	0.4 	(1.4)
Medical Devices 	5,369 	4,734 	13.4 	1.2 	12.2
Total Reportable Segments 	11,137 	10,373 	7.4 	0.5 	6.9
Other 	5 	4 	n/m 	n/m 	n/m
Net Sales 	$ 	11,142 $ 	10,377 	7.4 	0.5 	6.9
Total U.S. 	$ 	4,276 $ 	3,934 	8.7 	— 	8.7
Total International 	$ 	6,866 $ 	6,443 	6.6 	0.8 	5.8
Net Sales to External Customers
(in millions)
Six Months Ended
June 30, 2025
Six Months Ended
June 30, 2024
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products 	$ 	2,643 $ 	2,520 	4.9 % 	(2.9)% 	7.8 %
Nutritional Products 	4,358 	4,218 	3.3 	(1.5) 	4.8
Diagnostic Products 	4,227 	4,409 	(4.1) 	(0.9) 	(3.2)
Medical Devices 	10,264 	9,187 	11.7 	(0.7) 	12.4
Total Reportable Segments 	21,492 	20,334 	5.7 	(1.1) 	6.8
Other 	8 	7 	n/m 	n/m 	n/m
Net Sales 	$ 	21,500 $ 	20,341 	5.7 	(1.1) 	6.8
Total U.S. 	$ 	8,444 $ 	7,780 	8.5 	— 	8.5
Total International 	$ 	13,056 $ 	12,561 	3.9 	(1.9) 	5.8
___________________________________
Notes: 	In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year
average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
n/m = Percent change is not meaningful
25

-- 25 of 38 --

Table of Contents
The 6.9 percent increase in total net sales during the second quarter of 2025, excluding the impact of foreign exchange, primarily reflected higher product
sales in the Medical Devices and Established Pharmaceutical Products segments. Diagnostic Products sales continued to be impacted by the decline in
COVID-19 testing-related sales and the impact of volume-based procurement programs in China. COVID-19 testing-related sales were $55 million in the
second quarter of 2025 compared to $102 million in the second quarter of 2024. Abbott’s net sales were favorably impacted by changes in foreign
exchange rates in the second quarter as the relatively weaker U.S. dollar increased total international sales by 0.8 percent and total sales by 0.5 percent.
The 6.8 percent increase in total net sales during the first six months of 2025, excluding the impact of foreign exchange, reflected sales growth in the
Medical Devices and Established Pharmaceutical Products segments, fueled by higher sales of existing products, as well as the introduction of new
products. Diagnostic Products sales growth continued to be impacted by the decline in COVID-19 testing-related sales and the impact of volume-based
procurement programs in China. COVID-19 testing-related sales totaled $139 million during the first six months of 2025 and $306 million during the first
six months of 2024. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first six months as the relatively stronger
U.S. dollar at the beginning of the year decreased total international sales by 1.9 percent and total sales by 1.1 percent.
The table below provides detail by sales category for the six months ended June 30. Percent changes are versus the prior year and are based on unrounded
numbers.
(in millions) 	June 30, 2025 	June 30, 2024
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	2,024 $ 	1,916 	5.7 % 	(3.3)% 	9.0 %
Other Emerging Markets 	619 	604 	2.4 	(1.4) 	3.8
Nutritional Products —
International Pediatric Nutritionals 	920 	990 	(7.0) 	(2.4) 	(4.6)
U.S. Pediatric Nutritionals 	1,175 	1,078 	9.0 	— 	9.0
International Adult Nutritionals 	1,526 	1,417 	7.7 	(2.5) 	10.2
U.S. Adult Nutritionals 	737 	733 	0.6 	— 	0.6
Diagnostic Products —
Core Laboratory 	2,535 	2,534 	0.1 	(1.2) 	1.3
Molecular 	245 	256 	(4.4) 	(1.0) 	(3.4)
Point of Care 	290 	295 	(1.6) 	(0.4) 	(1.2)
Rapid Diagnostics 	1,157 	1,324 	(12.6) 	(0.6) 	(12.0)
Medical Devices —
Rhythm Management 	1,258 	1,169 	7.6 	(0.4) 	8.0
Electrophysiology 	1,329 	1,214 	9.5 	(0.6) 	10.1
Heart Failure 	707 	626 	13.1 	(0.2) 	13.3
Vascular 	1,467 	1,413 	3.8 	(0.7) 	4.5
Structural Heart 	1,213 	1,079 	12.5 	(0.7) 	13.2
Neuromodulation 	482 	469 	2.9 	(0.4) 	3.3
Diabetes Care 	3,808 	3,217 	18.4 	(0.7) 	19.1
26

-- 26 of 38 --

Table of Contents
In the first six months of 2025, total Established Pharmaceutical Products sales, excluding the impact of foreign exchange, increased 7.8 percent. Excluding
the unfavorable effect of foreign exchange, sales in Key Emerging Markets for Established Pharmaceutical Products increased 9.0 percent in the first six
months of 2025, led by higher revenue in several countries and across several therapeutic areas, including cardiometabolic, gastroenterology, and central
nervous system/pain management. Other Emerging Markets, excluding the effect of foreign exchange, increased 3.8 percent in the first six months of 2025.
Excluding the impact of foreign exchange, total Nutritional Products sales in the first six months of 2025 increased 4.8 percent. In U.S. Pediatric
Nutritionals, the 9.0 percent increase in sales in the first six months of 2025 reflects sales growth across the product portfolio. Excluding the effect of
foreign exchange, the 4.6 percent decrease in International Pediatric Nutritionals sales in the first six months of 2025 primarily reflects a decrease in sales
in the Asia Pacific region.
In the first six months of 2025, U.S. and International Adult Nutritionals sales, excluding the effect of foreign exchange, increased 0.6 percent and 10.2
percent, respectively, due to growth of Ensure and Glucerna product sales. U.S. Adult Nutritionals sales were partially offset by the discontinuation of
the ZonePerfect product line in March 2024.
In the first six months of 2025, Diagnostic Products sales decreased 3.2 percent, excluding the impact of foreign exchange, and increased 0.8 percent,
excluding the impact of foreign exchange and COVID-19 testing-related sales. In the first six months of 2025 and 2024, Abbott’s COVID-19 testing-
related sales totaled $139 million and $306 million, respectively.
In Core Laboratory, sales increased 1.3 percent in the first six months of 2025, excluding the effect of foreign exchange, due to continued deployment of
Abbott's Alinity testing platform, partially offset by the impact of volume-based procurement programs in China. In Rapid Diagnostics, sales decreased
12.0 percent in the first six months of 2025, excluding the effect of foreign exchange, primarily due to lower demand for COVID-19 tests.
Excluding the effect of foreign exchange, total Medical Devices sales increased 12.4 percent in the first six months of 2025, led by double-digit growth in
Diabetes Care, Heart Failure, Structural Heart and Electrophysiology. Higher Diabetes Care sales were driven by continued growth in Abbott's continuous
glucose monitoring (CGM) systems. CGM systems sales totaled $3.6 billion and $3.0 billion in the first six months of 2025 and 2024, respectively.
Excluding the effect of foreign exchange, CGM systems sales increased 20.5 percent in the first six months of 2025.
In Structural Heart, the 13.2 percent increase in sales, excluding the effect of foreign exchange, primarily reflects growth in TriClip and Navitor products.
In Heart Failure, the 13.3 percent increase in sales, excluding the effect of foreign exchange, primarily reflects growth in chronic and acute pump products
and related accessories. In Electrophysiology, the 10.1 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher
procedure volumes and increased demand for diagnostic and mapping catheters.
In Rhythm Management, the 8.0 percent sales increase in the first six months of 2025, excluding the impact of foreign exchange, was primarily due to
growth in Aveir leadless pacemakers, partially offset by a decrease in traditional pacemaker and implantable cardioverter defibrillator sales. In Vascular,
the 4.5 percent increase in sales, excluding the impact of foreign exchange, was primarily due to growth in vessel closure products, vascular imaging
products, and the Esprit™ (BTK) system, Abbott's below-the-knee resorbable stent.
In March 2025, Abbott obtained CE Mark for its Volt™ Pulsed Field Ablation (PFA) System to treat patients with atrial fibrillation. In May 2025, Abbott
announced U.S. Food and Drug Administration (FDA) approval of the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system to
treat people with mitral valve disease.
The gross profit margin percentage was 52.7 percent for the second quarter of 2025, compared to 51.1 percent for the second quarter of 2024, and 52.7
percent for the first six months of 2025 compared to 50.8 percent for the first six months of 2024. The increase in the first six months of 2025 reflects the
favorable impacts of gross margin improvement initiatives, partially offset by the unfavorable impact of foreign exchange.
Research and development (R&D) expenses increased $27 million to $725 million, or 3.9 percent, in the second quarter of 2025, and increased $59 million
to $1.4 billion, or 4.3 percent, in the first six months of 2025 compared to the prior year. The increase in R&D expenses in the first six months of 2025 was
primarily driven by higher spending on various projects.
® 	®
®
®
® 	®
®
27

-- 27 of 38 --

Table of Contents
Selling, general, and administrative (SG&A) expenses increased $155 million to $3.1 billion, or 5.3 percent, in the second quarter of 2025, and increased
$257 million to $6.2 billion, or 4.4 percent, in the first six months of 2025 compared to the prior year due to higher selling and marketing spending to drive
growth across various businesses. The increase in SG&A expenses in the first six months of 2025 was partially offset by the favorable impact of foreign
exchange.
Restructuring Plans
In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical
devices businesses. In the six months ended June 30, 2025, Abbott recorded employee related severance and other charges of $104 million, of which $69
million was recorded in Cost of products sold, $20 million was recorded in Research and development, and $15 million was recorded in Selling, general,
and administrative. Payments related to these actions totaled $21 million in the first six months of 2025 and the remaining liabilities totaled $83 million at
June 30, 2025. In addition, Abbott recognized asset impairment charges of $12 million related to these restructuring plans.
Other (Income) Expense, net
Other (income) expense, net increased from $10 million of expense in the second quarter of 2024 to $137 million of income in the second quarter of 2025
and increased from $101 million of income in the first six months of 2024 to $264 million of income in the first six months of 2025. The increase in the
second quarter and the first six months of 2025 is primarily due to the recognition of a $143 million loss on the sale of a non-core business related to the
Established Pharmaceutical Products segment in the second quarter of 2024. The increase in the first six months of 2025 also reflects lower investment
impairments and higher income associated with the non-service cost components of net pension and post-retirement medical benefit costs, partially offset
by changes in the fair value of contingent consideration liabilities related to previous business combinations.
Interest Expense, net
Interest expense, net decreased by $8 million to $50 million in the second quarter of 2025 and decreased by $20 million to $99 million in the first six
months of 2025. In the second quarter and the first six months of 2025, interest expense decreased primarily as a result of the repayment of long-term debt
in November 2024 and March 2025.
Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first six months of 2025 and 2024, taxes
on earnings include $84 million and $29 million, respectively, in excess tax benefits associated with share-based compensation. In the first six months of
2025, taxes on earnings includes approximately $300 million of tax expense related to a deferred tax asset that was recognized as a significant non-cash tax
benefit in a prior year. In the first six months of 2025 and 2024, taxes on earnings also included approximately $90 million of net tax benefit and $35
million of net tax expense, respectively, as the result of the resolution of various tax positions related to prior years.
In September 2023, Abbott received a Statutory Notice of Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS) for the 2019 Federal tax year
in the amount of $417 million. The primary adjustments proposed in the SNOD relate to the reallocation of income between Abbott’s U.S. entities and its
foreign affiliates. Abbott believes that the income reallocation adjustments proposed in the SNOD are without merit, in part because certain adjustments
contradict methods that were agreed to with the IRS in prior audit periods. The SNOD also contains other proposed adjustments that Abbott believes are
erroneous and unsupported. Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017 and 2018 Federal tax years in the amount of $192 million. The matters proposed in the
2017/2018 SNOD are substantially similar to the income allocation adjustments included in the 2019 SNOD. Abbott filed a petition in September 2024
with the U.S. Tax Court contesting the 2017/2018 SNOD in a manner consistent with its petition for the 2019 SNOD.
28

-- 28 of 38 --

Table of Contents
In October 2024, Abbott received a SNOD from the IRS for the 2020 Federal tax year assessing an additional $443 million of income tax. The primary
adjustments proposed in the SNOD are substantially similar to the income allocation adjustments included in the 2017/2018 and 2019 SNODs. Abbott
believes that the income reallocation adjustments proposed in the SNOD are without merit. The SNOD also contains other proposed adjustments and
omissions that Abbott believes are erroneous and unsupported. In addition to the tax assessment for the 2020 tax year, the 2020 SNOD also contested a
deduction for which an estimated $440 million cash tax benefit would be available in a different taxable year as allowed under applicable U.S. tax law.
Abbott filed a petition with the U.S. Tax Court contesting the SNOD in December 2024.
Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process and/or through
litigation as necessary. Abbott reserves for uncertain tax positions related to unresolved matters with the IRS and other taxing authorities. Abbott continues
to believe that its reserves for uncertain tax positions are appropriate.
The Organization for Economic Cooperation & Development (OECD) has proposed a two-pillared plan for a revised international tax system. Pillar 1
proposes to reallocate taxing rights among the jurisdictions in which in-scope multinational corporations operate. Pillar 2 proposes to assess a 15 percent
minimum tax on the earnings of in-scope multinational corporations on a country-by-country basis. Numerous countries have enacted legislation to adopt
the Pillar 2 model rules. The enactment of current Pillar 2 model rules did not and is not projected to have a material impact to Abbott's consolidated
financial statements. Abbott continues to monitor the Pillar 1 and Pillar 2 developments.
Liquidity and Capital Resources
The decrease in cash and cash equivalents from $7.6 billion at December 31, 2024, to $7.0 billion at June 30, 2025, reflects the repayment of debt in March
2025 of $1.0 billion and the payment of dividends and capital expenditures in the first six months of 2025, partially offset by cash generated from
operations. Working capital was $11.0 billion at June 30, 2025, and $9.5 billion at December 31, 2024. The increase in working capital in 2025 primarily
reflects increases in inventory and trade receivables.
In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first six months of 2025 totaled $3.5 billion, an increase
of $479 million from the prior year, primarily due to higher segment operating earnings. In the first six months of 2025, Net cash from operating activities
included $246 million of pension contributions and the payment of cash taxes of $945 million. Net cash from operating activities in the first six months of
2024 included $289 million of pension contributions and the payment of cash taxes of $747 million.
At June 30, 2025, Abbott’s long-term debt rating was AA- by S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott expects to maintain an
investment grade rating.
On March 17, 2025, Abbott repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity.
In October 2024, the board of directors authorized the repurchase of up to $7 billion of Abbott common shares, from time to time. The new authorization is
in addition to the $293 million unused portion of the share repurchase program authorized in December 2021.
In each of the first two quarters of 2025, Abbott declared a quarterly dividend of $0.59 per share on its common shares, which represents an increase of 7.3
percent over the $0.55 per share dividend declared in each of the first two quarters of 2024.
29

-- 29 of 38 --

Table of Contents
Legislative Issues
Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue
over the availability, method of delivery, and payment for healthcare products and services. It is not possible to predict the extent to which Abbott or the
healthcare industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1,
Business, and Item 1A, Risk Factors, in the 2024 Annual Report on Form 10-K.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by
Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release
publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
30

-- 30 of 38 --

Table of Contents
PART I. FINANCIAL INFORMATION
Item 4. Controls and Procedures
(a) Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Philip P. Boudreau,
evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and
concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose
in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of
1934 (the “Exchange Act”) is recorded, processed, summarized, and reported, within the time periods specified in the Commission’s rules and
forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is
accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate
to allow timely decisions regarding required disclosure.
(b) Changes in internal control over financial reporting. During the quarter ended June 30, 2025, there were no changes in Abbott’s internal control
over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to
materially affect, Abbott’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Abbott is involved in various claims, legal proceedings and investigations as described in its Annual Report on Form 10-K for the year ended December
31, 2024 (the “2024 10-K”), including those described below (as of June 30, 2025, except where noted below). While it is not feasible to predict the
outcome of such pending claims, proceedings, and investigations with certainty, management is of the opinion that their ultimate resolution should not have
a material adverse effect on Abbott's financial position, cash flows, or results of operations.
In the 2024 Form 10-K, Abbott reported that it is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis as a
result of being administered Abbott’s preterm infant formula products. Abbott further reported in the 2024 10-K that in April 2022, the U.S. Judicial Panel
on Multidistrict Litigation ordered all federal court cases consolidated for pretrial purposes in the U.S. District Court for the Northern District of Illinois. In
May 2025, the U.S. District Court for the Northern District of Illinois granted summary judgment in favor of Abbott on all claims in the first "bellwether"
case and entered judgment for Abbott. The plaintiff has filed a motion for reconsideration.
In addition, Abbott reported in the 2024 Form 10-K that in December 2022, it received a subpoena from the Enforcement Division of the Commission
requesting information relating to Abbott’s powder infant formula business and related public disclosures. In May 2025, the Enforcement Division of the
Commission informed Abbott that it had concluded its investigation and was not instituting an enforcement action.
31

-- 31 of 38 --

Table of Contents
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(c) Issuer Purchases of Equity Securities
Period
(a) Total
Number of
Shares (or
Units)
Purchased
(b) Average
Price Paid per
Share (or
Unit)
(c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
April 1, 2025 - April 30, 2025 	— 	$ 	— 	— $ 	7,293,222,352
May 1, 2025 - May 31, 2025 	— 	— 	— 	7,293,222,352
June 1, 2025 - June 30, 2025 	— 	— 	— 	7,293,222,352
Total 	— 	$ 	— 	— $ 	7,293,222,352
______________________________________
1. These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2. On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time (the "2021 Plan"). On October 11, 2024, the board
of directors authorized the repurchase of up to $7 billion of Abbott common shares, from time to time (the "2024 Plan"). The 2024 Plan is in addition to the unused portion of the 2021 Plan.
(1) 	(2)
(1) 	(2)
(1) 	(2)
(1) 	(2)
32

-- 32 of 38 --

Table of Contents
Item 6. Exhibits
Exhibit No. 	Exhibit
31.1 	Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2 	Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1 	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.
32.2 	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.
101 	The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and six
months ended June 30, 2025, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed
Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated
Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed
Consolidated Financial Statements.
104 	Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit
101).
33

-- 33 of 38 --

Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ABBOTT LABORATORIES
By: 	/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer
Date: July 30, 2025
34

-- 34 of 38 --

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
Abbott and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s
auditors and the audit committee of Abbott’s board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control
over financial reporting.
Date: July 30, 2025 	/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer

-- 35 of 38 --

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Philip P. Boudreau, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
Abbott and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s
auditors and the audit committee of Abbott’s board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control
over financial reporting.
Date: July 30, 2025 	/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer

-- 36 of 38 --

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended June 30, 2025 as filed with
the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ ROBERT B. FORD
Robert B. Ford
Chairman of the Board and Chief Executive Officer
July 30, 2025
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories
and furnished to the Securities and Exchange Commission or its staff upon request.

-- 37 of 38 --

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended June 30, 2025 as filed with
the Securities and Exchange Commission (the “Report”), I, Philip B. Boudreau, Executive Vice President, Finance and Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ PHILIP P. BOUDREAU
Philip P. Boudreau
Executive Vice President, Finance
and Chief Financial Officer
July 30, 2025
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories
and furnished to the Securities and Exchange Commission or its staff upon request.

-- 38 of 38 --